Market Overview:
The global midostaurin drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of leukemia and myelodysplastic syndromes (MDS) across the globe. In addition, rising awareness about these diseases and their treatment options is also contributing to the growth of this market. The global midostaurin drugs market can be segmented on the basis of type into acute myeloid leukemia (AML), MDS, and other types. On the basis of application, this market can be segmented into hospitals and pharmacies. Geographically, this market can be segmented into North America, Latin America, Europe, Asia Pacific and Middle East & Africa.
Product Definition:
Midostaurin is a drug that is used to treat cancer. It is important because it can help to stop the growth of cancer cells and may help to improve the prognosis for people with certain types of cancer.
AML:
Midostaurin is a kind of antibiotic that works by killing the bacteria. Some bacteria have developed resistance to this effect, so it is important to check for such bacterial infections before prescribing antibiotics. The most common types of infections found are urinary tract infection and pneumonia caused by Streptococcus pneumoniae ( pneumococcal disease or strep throat).
The American Liver Foundation states that around 1 in 25 people in the U.
MDS:
MDS or midostaurin is a drug that is used to treat diseases caused by viruses, bacteria, and parasites. It interferes with the growth of these disease-causing organisms. MDS has been known to be an effective cure for diseases like avian influenza (AI), Newcastle disease (ND), and bird flu.
Application Insights:
The hospital application segment led the market and accounted for more than 70% of the global revenue in 2017. The growing number of patients suffering from blood disorders, such as MDS and myelodysplastic syndromes (MDS), is expected to drive the demand for midostaurin drugs over the forecast period. In addition, an increase in cancer cases is anticipated to further propel growth over the coming years.
In addition, a rise in adoption of cost-effective therapies coupled with increasing awareness about available treatment options is expected to fuel demand from other applications including pharmacy and home healthcare during the forecast period. However, high costs associated with these therapies are anticipated to act as a major restraint for industry growth over next eight years or so.
Regional Analysis:
North America dominated the global midostaurin drugs market in 2017. This is due to the presence of a large number of patients suffering from MDS and AML, high healthcare expenditure, and availability of well-established healthcare facilities in this region. In addition, increasing government initiatives for research & development activities are also expected to drive growth during the forecast period. For instance, Fycompa (icatibant) was approved by FDA in June 2018 after it received approval by EMEA in January 2016 for treatment mid-malignant disease (MMD).
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising incidence rates of blood disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). According to data published on WHO website; there were 1.5 million new cases registered globally each year from 2012 till 2016 with China witnessing maximum cases followed by India.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is expected to drive the demand for midostaurin drugs in the coming years.
- Growing awareness about early diagnosis and treatment: There is a growing awareness among people about the importance of early diagnosis and treatment of cancer. This is likely to boost the demand for midostaurin drugs in the near future.
- Rising healthcare expenditure: The global healthcare expenditure is rising rapidly, owing to increasing income levels and technological advancements in the field of medicine. This is likely to create lucrative opportunities for players operating in the midostaurin drugs market over the forecast period.
- . Technological advancements: There has been a significant advancement in technology with respect to diagnostics and treatment options for cancer patients over recent years, which is expected to fuel growth prospects for players operating in this market during forecast period 2017-2025 .5) Emerging markets offer immense potential: The emerging markets are witnessing rapid economic development, which has led to an increase in disposable income levels among consumers therein These factors are anticipated create lucrative opportunities for players operating within Midostaurin Drugs market during forecast period 2017-2025
Scope Of The Report
Report Attributes
Report Details
Report Title
Midostaurin Drugs Market Research Report
By Type
AML, MDS, Other
By Application
Hospital, Pharmacy
By Companies
Novartis, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
191
Number of Tables & Figures
134
Customization Available
Yes, the report can be customized as per your need.
Global Midostaurin Drugs Market Report Segments:
The global Midostaurin Drugs market is segmented on the basis of:
Types
AML, MDS, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Novartis
Highlights of The Midostaurin Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AML
- MDS
- Other
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Midostaurin Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Midostaurin drugs are a class of medications used to treat various types of cancer. They work by blocking the growth of cancer cells.
Some of the key players operating in the midostaurin drugs market are Novartis, Novartis.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Midostaurin Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Midostaurin Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Midostaurin Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Midostaurin Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Midostaurin Drugs Market Size & Forecast, 2020-2028
4.5.1 Midostaurin Drugs Market Size and Y-o-Y Growth
4.5.2 Midostaurin Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 AML
5.2.2 MDS
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Midostaurin Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Midostaurin Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 AML
9.6.2 MDS
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 AML
10.6.2 MDS
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 AML
11.6.2 MDS
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 AML
12.6.2 MDS
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 AML
13.6.2 MDS
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Midostaurin Drugs Market: Competitive Dashboard
14.2 Global Midostaurin Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Novartis
